Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.

Motsch J, Murta de Oliveira C, Stus V, Köksal I, Lyulko O, Boucher HW, Kaye KS, File TM, Brown ML, Khan I, Du J, Joeng HK, Tipping RW, Aggrey A, Young K, Kartsonis NA, Butterton JR, Paschke A.

Clin Infect Dis. 2019 Aug 10. pii: ciz530. doi: 10.1093/cid/ciz530. [Epub ahead of print]

PMID:
31400759
2.

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-Seropositive Recipients of Allogeneic Hematopoietic-Cell Transplantation.

Ljungman P, Schmitt M, Marty FM, Maertens J, Chemaly RF, Kartsonis NA, Butterton JR, Wan H, Teal VL, Sarratt K, Murata Y, Leavitt RY, Badshah C.

Clin Infect Dis. 2019 Jun 8. pii: ciz490. doi: 10.1093/cid/ciz490. [Epub ahead of print]

PMID:
31179485
3.

A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia.

Arrieta AC, Sung L, Bradley JS, Zwaan CM, Gates D, Waskin H, Carmelitano P, Groll AH, Lehrnbecher T, Mangin E, Joshi A, Kartsonis NA, Walsh TJ, Paschke A.

PLoS One. 2019 Mar 26;14(3):e0212837. doi: 10.1371/journal.pone.0212837. eCollection 2019.

4.

Randomized Multicenter Study Comparing Safety and Efficacy of Daptomycin Versus Standard-of-care in Pediatric Patients With Staphylococcal Bacteremia.

Arrieta AC, Bradley JS, Popejoy MW, Bensaci M, Grandhi A, Bokesch P, Glasser C, Du L, Patino H, Kartsonis NA.

Pediatr Infect Dis J. 2018 Sep;37(9):893-900. doi: 10.1097/INF.0000000000001926.

PMID:
29406465
5.

Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.

Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, Haider S, Ullmann AJ, Katayama Y, Brown J, Mullane KM, Boeckh M, Blumberg EA, Einsele H, Snydman DR, Kanda Y, DiNubile MJ, Teal VL, Wan H, Murata Y, Kartsonis NA, Leavitt RY, Badshah C.

N Engl J Med. 2017 Dec 21;377(25):2433-2444. doi: 10.1056/NEJMoa1706640. Epub 2017 Dec 6.

6.

Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.

Cornely OA, Robertson MN, Haider S, Grigg A, Geddes M, Aoun M, Heinz WJ, Raad I, Schanz U, Meyer RG, Hammond SP, Mullane KM, Ostermann H, Ullmann AJ, Zimmerli S, Van Iersel MLPS, Hepler DA, Waskin H, Kartsonis NA, Maertens J.

J Antimicrob Chemother. 2017 Dec 1;72(12):3501. doi: 10.1093/jac/dkx382. No abstract available.

PMID:
29029280
7.

Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.

Cornely OA, Robertson MN, Haider S, Grigg A, Geddes M, Aoun M, Heinz WJ, Raad I, Schanz U, Meyer RG, Hammond SP, Mullane KM, Ostermann H, Ullmann AJ, Zimmerli S, Van Iersel MLPS, Hepler DA, Waskin H, Kartsonis NA, Maertens J.

J Antimicrob Chemother. 2017 Dec 1;72(12):3406-3413. doi: 10.1093/jac/dkx263. Erratum in: J Antimicrob Chemother. 2017 Dec 1;72(12):3501.

PMID:
28961714
8.

Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.

Sims M, Mariyanovski V, McLeroth P, Akers W, Lee YC, Brown ML, Du J, Pedley A, Kartsonis NA, Paschke A.

J Antimicrob Chemother. 2017 Sep 1;72(9):2616-2626. doi: 10.1093/jac/dkx139.

PMID:
28575389
9.

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.

Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim YS, Yoshida J, Gabryelski L, Pedley A, Eves K, Tipping R, Guris D, Kartsonis N, Dorr MB; MODIFY I and MODIFY II Investigators.

N Engl J Med. 2017 Jan 26;376(4):305-317. doi: 10.1056/NEJMoa1602615.

10.

Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection.

Lucasti C, Vasile L, Sandesc D, Venskutonis D, McLeroth P, Lala M, Rizk ML, Brown ML, Losada MC, Pedley A, Kartsonis NA, Paschke A.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6234-43. doi: 10.1128/AAC.00633-16. Print 2016 Oct.

11.

Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.

Cornely OA, Duarte RF, Haider S, Chandrasekar P, Helfgott D, Jiménez JL, Candoni A, Raad I, Laverdiere M, Langston A, Kartsonis N, Van Iersel M, Connelly N, Waskin H.

J Antimicrob Chemother. 2016 Jun;71(6):1747. doi: 10.1093/jac/dkw079. Epub 2016 Mar 8. No abstract available.

PMID:
26960721
12.

Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.

Cornely OA, Duarte RF, Haider S, Chandrasekar P, Helfgott D, Jiménez JL, Candoni A, Raad I, Laverdiere M, Langston A, Kartsonis N, Van Iersel M, Connelly N, Waskin H.

J Antimicrob Chemother. 2016 Mar;71(3):718-26. doi: 10.1093/jac/dkv380. Epub 2015 Nov 26. Erratum in: J Antimicrob Chemother. 2016 Jun;71(6):1747.

PMID:
26612870
13.

Pharmacokinetics, efficacy, and safety of caspofungin in Japanese pediatric patients with invasive candidiasis and invasive aspergillosis.

Mori M, Imaizumi M, Ishiwada N, Kaneko T, Goto H, Kato K, Hara J, Kosaka Y, Koike K, Kawamoto H, Maeda N, Yoshinari T, Kishino H, Takahashi K, Kawahara S, Kartsonis NA, Komada Y.

J Infect Chemother. 2015 Jun;21(6):421-6. doi: 10.1016/j.jiac.2015.01.009. Epub 2015 Jan 30.

PMID:
25701307
14.

Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.

Duarte RF, López-Jiménez J, Cornely OA, Laverdiere M, Helfgott D, Haider S, Chandrasekar P, Langston A, Perfect J, Ma L, van Iersel ML, Connelly N, Kartsonis N, Waskin H.

Antimicrob Agents Chemother. 2014 Oct;58(10):5758-65. doi: 10.1128/AAC.03050-14. Epub 2014 Jul 21.

15.

Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.

Maertens J, Cornely OA, Ullmann AJ, Heinz WJ, Krishna G, Patino H, Caceres M, Kartsonis N, Waskin H, Robertson MN.

Antimicrob Agents Chemother. 2014 Jul;58(7):3610-7. doi: 10.1128/AAC.02686-13. Epub 2014 Apr 14.

16.

Caspofungin exposure-response relationships in adult patients with mucosal or invasive candidiasis.

Comisar W, Sun P, Li S, Sable C, Schwartz M, Bi S, Chow J, Ngai A, Winchell G, Kartsonis N, Stone J.

Clin Pharmacol Drug Dev. 2014 Jan;3(1):43-50. doi: 10.1002/cpdd.44. Epub 2013 Jul 5.

PMID:
27128229
17.

Naturally occurring IgG antibody levels to the Staphylococcus aureus protein IsdB in humans.

Zorman JK, Esser M, Raedler M, Kreiswirth BN, Ala'Aldeen DA, Kartsonis N, Smugar SS, Anderson AS, McNeely T, Arduino JM.

Hum Vaccin Immunother. 2013 Sep;9(9):1857-64. doi: 10.4161/hv.25253. Epub 2013 Jun 18.

18.

Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial.

Fowler VG, Allen KB, Moreira ED, Moustafa M, Isgro F, Boucher HW, Corey GR, Carmeli Y, Betts R, Hartzel JS, Chan IS, McNeely TB, Kartsonis NA, Guris D, Onorato MT, Smugar SS, DiNubile MJ, Sobanjo-ter Meulen A.

JAMA. 2013 Apr 3;309(13):1368-78. doi: 10.1001/jama.2013.3010.

PMID:
23549582
19.

A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis.

Kohno S, Izumikawa K, Yoshida M, Takesue Y, Oka S, Kamei K, Miyazaki Y, Yoshinari T, Kartsonis NA, Niki Y.

Eur J Clin Microbiol Infect Dis. 2013 Mar;32(3):387-97. doi: 10.1007/s10096-012-1754-z. Epub 2012 Oct 3.

20.

Phase IIa study of the immunogenicity and safety of the novel Staphylococcus aureus vaccine V710 in adults with end-stage renal disease receiving hemodialysis.

Moustafa M, Aronoff GR, Chandran C, Hartzel JS, Smugar SS, Galphin CM, Mailloux LU, Brown E, Dinubile MJ, Kartsonis NA, Guris D.

Clin Vaccine Immunol. 2012 Sep;19(9):1509-16. doi: 10.1128/CVI.00034-12. Epub 2012 Jul 25.

21.

The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): results of two Phase I studies.

Harro CD, Betts RF, Hartzel JS, Onorato MT, Lipka J, Smugar SS, Kartsonis NA.

Vaccine. 2012 Feb 21;30(9):1729-36. doi: 10.1016/j.vaccine.2011.12.045. Epub 2011 Dec 20.

PMID:
22192849
22.

Overview of safety experience with caspofungin in clinical trials conducted over the first 15 years: a brief report.

Ngai AL, Bourque MR, Lupinacci RJ, Strohmaier KM, Kartsonis NA.

Int J Antimicrob Agents. 2011 Dec;38(6):540-4. doi: 10.1016/j.ijantimicag.2011.07.008. Epub 2011 Sep 16. Review.

PMID:
21925846
23.

Efficacy and safety of caspofungin in obese patients.

Ryan DM, Lupinacci RJ, Kartsonis NA.

Med Mycol. 2011 Oct;49(7):748-54. doi: 10.3109/13693786.2011.571293.

PMID:
21466264
24.

Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients.

Li CC, Sun P, Dong Y, Bi S, Desai R, Dockendorf MF, Kartsonis NA, Ngai AL, Bradshaw S, Stone JA.

Antimicrob Agents Chemother. 2011 May;55(5):2098-105. doi: 10.1128/AAC.00905-10. Epub 2011 Feb 7.

25.

Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans.

Harro C, Betts R, Orenstein W, Kwak EJ, Greenberg HE, Onorato MT, Hartzel J, Lipka J, DiNubile MJ, Kartsonis N.

Clin Vaccine Immunol. 2010 Dec;17(12):1868-74. doi: 10.1128/CVI.00356-10. Epub 2010 Oct 13.

26.

A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.

Maertens JA, Madero L, Reilly AF, Lehrnbecher T, Groll AH, Jafri HS, Green M, Nania JJ, Bourque MR, Wise BA, Strohmaier KM, Taylor AF, Kartsonis NA, Chow JW, Arndt CA, DePauw BE, Walsh TJ; Caspofungin Pediatric Study Group.

Pediatr Infect Dis J. 2010 May;29(5):415-20. doi: 10.1097/INF.0b013e3181da2171.

PMID:
20431381
27.

Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database.

Colombo AL, Ngai AL, Bourque M, Bradshaw SK, Strohmaier KM, Taylor AF, Lupinacci RJ, Kartsonis NA.

Antimicrob Agents Chemother. 2010 May;54(5):1864-71. doi: 10.1128/AAC.00911-09. Epub 2010 Mar 15.

28.

Safety experience with caspofungin in pediatric patients.

Zaoutis T, Lehrnbecher T, Groll AH, Steinbach WJ, Jafri HS, Maertens J, Ngai AL, Chow JW, Taylor AF, Strohmaier KM, Bourque M, Bradshaw SK, Petrecz M, Kartsonis NA.

Pediatr Infect Dis J. 2009 Dec;28(12):1132-5. doi: 10.1097/INF.0b013e3181af5a15.

PMID:
19779392
29.

A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis.

Betts RF, Nucci M, Talwar D, Gareca M, Queiroz-Telles F, Bedimo RJ, Herbrecht R, Ruiz-Palacios G, Young JA, Baddley JW, Strohmaier KM, Tucker KA, Taylor AF, Kartsonis NA; Caspofungin High-Dose Study Group.

Clin Infect Dis. 2009 Jun 15;48(12):1676-84. doi: 10.1086/598933.

PMID:
19419331
30.

Serologic assay to quantify human immunoglobulin G antibodies to the Staphylococcus aureus iron surface determinant B antigen.

Raedler MD, Heyne S, Wagner E, Shalkowski SK, Secore S, Anderson AS, Cook J, Cope L, McNeely T, Retzlaff M, Shanter J, Rubinstein LJ, Green T, Kartsonis N, Esser MT.

Clin Vaccine Immunol. 2009 May;16(5):739-48. doi: 10.1128/CVI.00478-08. Epub 2009 Mar 25.

31.

A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients.

Zaoutis TE, Jafri HS, Huang LM, Locatelli F, Barzilai A, Ebell W, Steinbach WJ, Bradley J, Lieberman JM, Hsiao CC, Seibel N, Laws HJ, Gamba M, Petrecz M, Taylor AF, Strohmaier KM, Chow JW, Kartsonis NA, Ngai AL.

Pediatrics. 2009 Mar;123(3):877-84. doi: 10.1542/peds.2008-1158.

PMID:
19255017
32.

Pharmacokinetics and safety of caspofungin in older infants and toddlers.

Neely M, Jafri HS, Seibel N, Knapp K, Adamson PC, Bradshaw SK, Strohmaier KM, Sun P, Bi S, Dockendorf MF, Stone JA, Kartsonis NA.

Antimicrob Agents Chemother. 2009 Apr;53(4):1450-6. doi: 10.1128/AAC.01027-08. Epub 2008 Dec 29.

33.

Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age.

Sáez-Llorens X, Macias M, Maiya P, Pineros J, Jafri HS, Chatterjee A, Ruiz G, Raghavan J, Bradshaw SK, Kartsonis NA, Sun P, Strohmaier KM, Fallon M, Bi S, Stone JA, Chow JW.

Antimicrob Agents Chemother. 2009 Mar;53(3):869-75. doi: 10.1128/AAC.00868-08. Epub 2008 Dec 15.

34.

Efficacy and safety of caspofungin therapy in elderly patients with proven or suspected invasive fungal infections.

Dinubile MJ, Strohmaier KM, Lupinacci RJ, Meibohm AR, Sable CA, Kartsonis NA.

Eur J Clin Microbiol Infect Dis. 2008 Aug;27(8):663-70. doi: 10.1007/s10096-008-0486-6. Epub 2008 Mar 7.

PMID:
18324427
35.

Efficacy and safety of caspofungin in solid organ transplant recipients.

Petrovic J, Ngai A, Bradshaw S, Williams-Diaz A, Taylor A, Sable C, Vuocolo S, Kartsonis N.

Transplant Proc. 2007 Dec;39(10):3117-20.

PMID:
18089335
36.

Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial.

DiNubile MJ, Lupinacci RJ, Strohmaier KM, Sable CA, Kartsonis NA.

J Crit Care. 2007 Sep;22(3):237-44. Epub 2007 Apr 10.

PMID:
17869975
37.

Caspofungin for the treatment of less common forms of invasive candidiasis.

Cornely OA, Lasso M, Betts R, Klimko N, Vazquez J, Dobb G, Velez J, Williams-Diaz A, Lipka J, Taylor A, Sable C, Kartsonis N.

J Antimicrob Chemother. 2007 Aug;60(2):363-9. Epub 2007 May 26.

PMID:
17526917
38.

Caspofungin in the treatment of symptomatic candiduria.

Sobel JD, Bradshaw SK, Lipka CJ, Kartsonis NA.

Clin Infect Dis. 2007 Mar 1;44(5):e46-9. Epub 2007 Jan 22.

PMID:
17278048
39.

Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis.

Maertens J, Glasmacher A, Herbrecht R, Thiebaut A, Cordonnier C, Segal BH, Killar J, Taylor A, Kartsonis N, Patterson TF, Aoun M, Caillot D, Sable C; Caspofungin Combination Therapy Study Group.

Cancer. 2006 Dec 15;107(12):2888-97.

40.

Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients.

Betts R, Glasmacher A, Maertens J, Maschmeyer G, Vazquez JA, Teppler H, Taylor A, Lupinacci R, Sable C, Kartsonis N.

Cancer. 2006 Jan 15;106(2):466-73. Review.

41.

Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents.

Walsh TJ, Adamson PC, Seibel NL, Flynn PM, Neely MN, Schwartz C, Shad A, Kaplan SL, Roden MM, Stone JA, Miller A, Bradshaw SK, Li SX, Sable CA, Kartsonis NA.

Antimicrob Agents Chemother. 2005 Nov;49(11):4536-45.

42.

Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome.

Kartsonis N, Killar J, Mixson L, Hoe CM, Sable C, Bartizal K, Motyl M.

Antimicrob Agents Chemother. 2005 Sep;49(9):3616-23.

43.

Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study.

Maertens J, Glasmacher A, Selleslag D, Ngai A, Ryan D, Layton M, Taylor A, Sable C, Kartsonis N.

Clin Infect Dis. 2005 Jul 1;41(1):e9-14. Epub 2005 May 17.

PMID:
15937754
44.

Invasive candidiasis in cancer patients: observations from a randomized clinical trial.

DiNubile MJ, Hille D, Sable CA, Kartsonis NA.

J Infect. 2005 Jun;50(5):443-9.

PMID:
15907554
45.

Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study.

Kartsonis NA, Saah AJ, Joy Lipka C, Taylor AF, Sable CA.

J Infect. 2005 Apr;50(3):196-205.

PMID:
15780413
46.

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.

Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, Sable CA, Kartsonis NA, Ngai A, Taylor A, Patterson TF, Denning DW, Walsh TJ; Caspofungin Salvage Aspergillosis Study Group.

Clin Infect Dis. 2004 Dec 1;39(11):1563-71. Epub 2004 Nov 9.

PMID:
15578352
47.

Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A.

Marr KA, Hachem R, Papanicolaou G, Somani J, Arduino JM, Lipka CJ, Ngai AL, Kartsonis N, Chodakewitz J, Sable C.

Transpl Infect Dis. 2004 Sep;6(3):110-6.

PMID:
15569226
48.

Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study.

Kartsonis NA, Saah A, Lipka CJ, Taylor A, Sable CA.

J Antimicrob Chemother. 2004 May;53(5):878-81. Epub 2004 Mar 24.

PMID:
15044431
49.

Caspofungin: the first in a new class of antifungal agents.

Kartsonis NA, Nielsen J, Douglas CM.

Drug Resist Updat. 2003 Aug;6(4):197-218. Review.

PMID:
12962685
50.

Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis.

Colombo AL, Perfect J, DiNubile M, Bartizal K, Motyl M, Hicks P, Lupinacci R, Sable C, Kartsonis N.

Eur J Clin Microbiol Infect Dis. 2003 Aug;22(8):470-4. Epub 2003 Jul 23.

PMID:
12884068

Supplemental Content

Loading ...
Support Center